Eli Lilly Sues Sellers of Black Market Weight-Loss Drugs

WSJ · August 12, 2026

Generating summary...

Enjoying OptionsWhisper?

Built by a solo developer. Free and curated for you.

Rate on the App Store Upgrade to Pro

Original at WSJ → Search for more →

More from the feed

FT Eli Lilly and Novo Nordisk raise profit outlook as weight-loss drug demand soars 7d ago

WSJ Eli Lilly Posts Higher Revenue on Continued GLP-1 Demand 7d ago

WSJ CVS Health Launches Eli Lilly GLP-1 Partnership, Lifts Outlook as Profit Increases 7d ago

BLOOMBERG Eli Lilly Ripe for Stock Split After Obesity Drug-Fueled Rally 8d ago

WSJ Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results. www.wsj.com/health/pharm... 20d ago

OptionsWhisperThe market, whispered.›